Evercore Wealth Management’s Celldex Therapeutics CLDX Stock Holding History

Evercore Wealth Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-522	Closed	-$218K	–	1064
2015 Q1	$218K	Hold	522	–	–	0.01%	405
2014 Q4	$143K	Hold	522	–	–	0.01%	407
2014 Q3	$102K	Hold	522	–	–	0.01%	510
2014 Q2	$128K	Buy	522 +466	+832%	+$105K	0.01%	470
2014 Q1	$15K	Hold	56	–	–	﹤0.01%	777
2013 Q4	$20K	Hold	56	–	–	﹤0.01%	683
2013 Q3	$30K	Hold	56	–	–	﹤0.01%	626
2013 Q2	$13K	Buy	+56	New	+$11K	﹤0.01%	700

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Evercore Wealth Management's CLDX Position: Q2 2015 in Review

Evercore Wealth Management sold out of Celldex Therapeutics (CLDX) in Q2 2015, closing a stake of 522 shares — an estimated $218K sold.

Evercore Wealth Management first reported a position in CLDX in Q2 2013 and held it in 8 quarters. The position peaked at $218K in Q1 2015. 186 funds tracked by Wall St. Rank hold CLDX as of Q2 2015.

Evercore Wealth Management reported no remaining Celldex Therapeutics position as of Q2 2015 after selling out during the quarter.
Evercore Wealth Management sold 522 Celldex Therapeutics shares in Q2 2015, an estimated $218K.
Evercore Wealth Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 8 quarters.
Evercore Wealth Management's Celldex Therapeutics position peaked at $218K in Q1 2015.
186 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2015.

Based on Evercore Wealth Management's 13F filing for Q2 2015, filed 6 Aug 2015.